ObsEva SA.

+0.02 (+1.06%)
4:01:28 PM EDT: $1.91 0.00 (0.00%)
Regulatory, Earnings Announcements

Obseva Announces Topline Results For Linzagolix

Published: 01/06/2022 06:12 GMT
ObsEva SA. (OBSV) - Obseva Announces Positive Topline Results for Linzagolix 200 Mg With Add-back Therapy in the Phase 3 Edelweiss 3 Trial in Patients With Moderate-to-severe Endometriosis-associated Pain.
Once Daily Linzagolix 200 Mg With Abt Met Both Co-primary Efficacy Objectives, Demonstrating Reductions in Dysmenorrhea and Non-menstrual Pelvic Pain Versus Placebo at 3 Months; Showed Statistically Significant and Clinically Meaningful Improvements Versus Placebo in Ranked Secondary Endpoints of Dysmenorrhea, Non-menstrual Pelvic Pain, Dyschezia, Overall Pelvic Pain, and Ability to Perform Daily Activities at 6 Months.
Additional Data From Post-treatment Follow-up of Edelweiss 3 Are Expected in 2q 2022 and From Post-treatment Follow-up of Extension Study in 4q 2022-.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.22

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.24

More details on our Analysts Page.